Ian Bouligny

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies”.

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0.165DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Augmenting Venetoclax Activity Through Signal Transduction in AML

Journal of Cellular Signaling(2023)10.33696/signaling.4.085

N/A

0DataRank · unranked

6 citations

Keri Maher, Steven Grant, Ian Bouligny

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Research Square(2023)10.21203/rs.3.rs-3015916/v1

N/A

0DataRank · unranked

4 citations

Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Josh Boron +10 more

Efficacy of 10-day decitabine in acute myeloid leukemia

Leukemia Research(2021)10.1016/j.leukres.2021.106524

N/A

0DataRank · unranked

10 citations

Vivek Mehta, Scott Isom, Leslie R. Ellis, Rupali Bhave, Dianna S. Howard +6 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia

European Journal Of Haematology(2024)10.1111/ejh.14308

N/A

0DataRank · unranked

5 citations

Ian Bouligny, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan A. Wages +3 more

Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives

Blood Reviews(2022)10.1016/j.blre.2022.100996

N/A

0DataRank · unranked

37 citations

Keri Maher, Steven Grant, Ian Bouligny

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

eJHaem(2023)10.1002/jha2.663

N/A

0DataRank · unranked

18 citations

Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran +9 more